Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs CoreAge Rx

Belle Health
Graded #48

Lower grade

vs+14.799999999999997
CoreAge Rx
Graded #1

Higher grade

The verdict

CoreAge Rx takes it — 91.8/100 to 77/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
92
92
Dose & formulationCoreAge Rx +16
72
88
Clinical oversightCoreAge Rx +22
71
93
Labs & monitoringCoreAge Rx +18
72
90
FulfillmentCoreAge Rx +10
85
95
Contract termsCoreAge Rx +41
55
96
Belle Health · left barCoreAge Rx · right bar

The numbers

MetricBelle HealthCoreAge Rx
WeighScore77/10091.8/100
GradeC+A−
Scorecard rank#48#1
Semaglutide$119/mo$149/mo
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$349/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard